Applications published 8 April 2009

Novel phosphorus-calcium-strontium compound and uses thereof
Centre National de la Recherche Scientifique; Universite de Montpellier 2043587*

Barrier film-forming germicidal compsn for controlling mastitis
Delaval 2043590*

Extended release perforated tablet
Board of Trustees of the University of Arkansas 2043598*

Inhalant formulation containing sulphoalkyl ether cyclodextrin and corticosteroid
CyDex Pharmaceuticals 2043599*

Pharmaceutical formulations for the sustained release of active ingredient(s) as well as their applications, especially therapeutic
Flamel Technologies 2043600*

Aqueous gel formulation and method for inducing topical anaesthesia
Akorn 2043601*

Cyclosporin compsns
Allergan 2043602*

Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
Arubor 2043603*

Topical compsns
Dr Reddy's Laboratories Ltd; Dr Reddy's Laboratories Inc 2040604*

Injectable slow-release formulation of active ingredients, method for the preparation thereof
Societe'd'Exploitation de Produits pour les Industries Chimiques 2043605*

Nanoparticle kinase inhibitor formulations
Elan Pahram International 2043606*

Process for the preparation of micronised valsartan
USV  2043607*

• Powders for reconstitution
Tibotec Pharmaceuticals 2043608*

• Pellet formulation comprising colloidal silicon dioxide
University of Sunderland 2043609*

• Drying of drug-containing particles
Pfizer Products 2043610*

• Metal-containing formulations and methods of use
Nucryst Pharmaceuticals 2043611*

• A stable olanzapine formulation with antioxidants
Bilim Ilac Sanayii Ve Ticaret 2043612*

• Solid form
FMC  2043614*

• Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
Sandoz 2043615*

• Pharmaceutical compsns comprising levetiracetam
UCB Pharma 2043616*

• N-terminal derivatisation of proteins with polysaccharides
Lipoxen Technologies 2043616*

• Analyte monitoring and therapy management system and methods therefor
Abbott Diabetes Care 2043617*

• Pharmaceutical formulation comprising donepezil
Pliva Hrvatska 2043618*

• Chewable tablet containing penylephrine
Wyeth 2043619*

• Compsns and methods for treating parasitic infections
Tyratech 2043620*

• Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
Metaproteomics 2043621*

• Beta acid based protein kinase modulation cancer treatment
Metaproteomics 2043622*

• Nanoparticulate formulations of modafinil
Elan Corp 2043623*

• Combination of modafinil and an antagonist or inverse agonist of the H3 receptor
Bioproject 2043624*

• NFKAPPAB inhibitors to treat pain locally
Medtronic 2043625*

• Compsn comprising a retinoid and benzoyl peroxide
Galderma Research & Development 2043626*

• Iron (II) containing treatments for hyperphosphatemia
Genzyme 2043627*

• Ultraviolet absorbing ophthalmic compsns
Riolan Technologies 2043628*

• 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
Bayer Schering Pharma 2043629*

• 6,9-disubstituted purine derivatives and their use for treating skin
Institute of Experimental Botany, Academy of Sciences of the Czech Republic 2043630*

• New indicators for direct thrombin inhibitors in the cardiovascular field
Boehringer Ingelheim International 2043631*

• New indicators for direct thrombin inhibitors
Boehringer Ingelheim International 2043632*

• Thiadiazolidinone derivatives
University of Rochester 2043633*

• Substituted pyrazoles as ghrelin receptor antagonists
Merck & Co 2043634*

• Pharmaceutical combinations
Astex Therapeutics 2043635*

• (Combi) compsns for the treatment of mucormycosis comprising iron chelator and anti-fungal agent
Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center 2043636*

• Methods and medicaments for administration of ibuprofen
Horizon Therapeutics 2043637*

• Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
Novartis; Novartis Pharma 2043638*

• Processes for preparing polymorphic forms of solifenacin succinate
Teva Pharmaceutical Industries 2043639*

• CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients
Pfizer Products 2043640*

• Combinations of monoamine reuptake inhibitors and potassium channel activators
NeuroSearch 2043641*